Explore more publications!
Africa Daily Journal
Got News to Share?

Africa Daily Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Africa Daily Journal.

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

January 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

February 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28

Press releases published on January 6, 2026

A Better Place: The Story Behind the Song that Started a Worldwide Movement
Jan. 6, 2026

A Better Place: The Story Behind the Song that Started a Worldwide Movement

Indeterminate EIN Presswire
JXEPC Launches Next-Generation DC Submerged Arc Furnace
Jan. 6, 2026

JXEPC Launches Next-Generation DC Submerged Arc Furnace

Indeterminate EIN Presswire
BitMEX lanza Equity Perps para trading de acciones 24/7
Jan. 6, 2026

BitMEX lanza Equity Perps para trading de acciones 24/7

Indeterminate GlobeNewswire
OR Royalties Announces Preliminary Q4 2025 GEO Deliveries Along With Record Annual Revenues and C$50.8 Million of Share Repurchases Under the Normal Course Issuer Bid in 2025
Jan. 6, 2026

OR Royalties Announces Preliminary Q4 2025 GEO Deliveries Along With Record Annual Revenues and C$50.8 Million of Share Repurchases Under the Normal Course Issuer Bid in 2025

Indeterminate GlobeNewswire
Redevances OR annonce les livraisons préliminaires d’onces d’équivalent d’or pour le quatrième trimestre de 2025 et des produits annuels records et 50,8 millions de dollars canadiens en rachats d’actions dans le cadre de l’offre publique de rachat dans…
Jan. 6, 2026

Redevances OR annonce les livraisons préliminaires d’onces d’équivalent d’or pour le quatrième trimestre de 2025 et des produits annuels records et 50,8 millions de dollars canadiens en rachats d’actions dans le cadre de l’offre publique de rachat dans…

Indeterminate GlobeNewswire
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
Jan. 6, 2026

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Indeterminate GlobeNewswire
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
Jan. 6, 2026

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

Indeterminate GlobeNewswire
Teclison, Inc. to Participate in ASCO Gastrointestinal Cancers Symposium
Jan. 6, 2026

Teclison, Inc. to Participate in ASCO Gastrointestinal Cancers Symposium

Indeterminate GlobeNewswire
Dewpoint Therapeutics Launches Initiative to Build Viral Condensate Phenomics Atlas for HPV
Jan. 6, 2026

Dewpoint Therapeutics Launches Initiative to Build Viral Condensate Phenomics Atlas for HPV

Indeterminate GlobeNewswire
Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative
Jan. 6, 2026

Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative

Indeterminate GlobeNewswire
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development
Jan. 6, 2026

Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

Indeterminate GlobeNewswire
Sparrow Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Clofutriben for Difficult-to-Control Type 2 Diabetes
Jan. 6, 2026

Sparrow Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Clofutriben for Difficult-to-Control Type 2 Diabetes

Indeterminate GlobeNewswire
Seismic Therapeutic Announces Updated Presentation Time at the 44th Annual J.P. Morgan Healthcare Conference
Jan. 6, 2026

Seismic Therapeutic Announces Updated Presentation Time at the 44th Annual J.P. Morgan Healthcare Conference

Indeterminate GlobeNewswire
Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency
Jan. 6, 2026

Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency

Indeterminate GlobeNewswire
Maxus Mining Highlights Historical Polymetallic Results at the Quarry Project in British Columbia, Canada
Jan. 6, 2026

Maxus Mining Highlights Historical Polymetallic Results at the Quarry Project in British Columbia, Canada

Indeterminate GlobeNewswire
Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
Jan. 6, 2026

Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Indeterminate GlobeNewswire
Galecto Announces Key Additions to Leadership Team
Jan. 6, 2026

Galecto Announces Key Additions to Leadership Team

Indeterminate GlobeNewswire
Atsena Therapeutics Appoints McDavid Stilwell as Chief Financial Officer
Jan. 6, 2026

Atsena Therapeutics Appoints McDavid Stilwell as Chief Financial Officer

Indeterminate GlobeNewswire
Rio Silver Highlights High-Grade Silver up to 6.26 g/t Au and 991 g/t Ag (28.9 oz per metric tonne) over 0.70 metres at Maria Norte and Advances a Clear Near-Term Development Path in Peru
Jan. 6, 2026

Rio Silver Highlights High-Grade Silver up to 6.26 g/t Au and 991 g/t Ag (28.9 oz per metric tonne) over 0.70 metres at Maria Norte and Advances a Clear Near-Term Development Path in Peru

Indeterminate GlobeNewswire
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan. 6, 2026

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions